Literature DB >> 26910601

Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.

Tilman Todenhöfer1, Jörg Hennenlotter2, Nathalie Dorner2, Ursula Kühs2, Stefan Aufderklamm2, Steffen Rausch2, Simone Bier2, Johannes Mischinger2, Doreen Schellbach3, Siegfried Hauch3, Natalie Feniuk3, Jens Bedke2, Georgios Gakis2, Arnulf Stenzl2, Christian Schwentner2.   

Abstract

PURPOSE: There is increasing interest in circulating tumor cells (CTCs) as a biomarker in bladder cancer (BC). In the present pilot study, we used a platform originally developed for detection of breast cancer CTCs to assess breast cancer-associated transcripts in CTCs of patients with different stages of BC. Moreover, transcripts specific for cancer stem cells and epithelial mesenchymal transition (EMT) were assessed.
METHODS: We prospectively enrolled 83 BC patients and 29 controls. The AdnaTest® system was used to enrich epithelial cells in peripheral blood and to detect breast cancer-associated, stem cell-specific or EMT-specific transcripts. Test results were correlated with clinical and pathological stage.
RESULTS: A positive AdnaTest® BreastCancerDetect was present in 6.9 % of controls (group A), 6.7, 15.0 and 18.7 % of patients with non-muscle-invasive BC (B), cM0 muscle-invasive BC (C) and metastatic BC (D) (p = 0.13). Stem cell-specific transcripts in group A, B, C and D were detected in 10.3, 10.0, 22.5 and 31.3 % (p = 0.03). EMT-associated transcripts were present in 3.5, 3.3, 15.0 and 18.7 % (p = 0.03). In group C, epithelial and stem-like transcripts correlated with tumor stage (p = 0.01 and 0.04).
CONCLUSIONS: CTCs with expression of breast cancer-associated transcripts are present in a considerable proportion of patients with BC. EMT and stem cell-specific transcripts of CTCs correlate with clinical stage and can be detected in patients negative for epithelial transcripts. The prognostic relevance of AdnaTest® results in BC patients and potential implications for therapy decisions remain to be determined in prospective studies.

Entities:  

Keywords:  AdnaTest; Biomarker; Bladder cancer; Circulating tumor cells

Mesh:

Substances:

Year:  2016        PMID: 26910601     DOI: 10.1007/s00432-016-2129-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

1.  Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.

Authors:  Michael Rink; Felix K Chun; Roland Dahlem; Armin Soave; Sarah Minner; Jens Hansen; Malgorzata Stoupiec; Cornelia Coith; Luis A Kluth; Sascha A Ahyai; Martin G Friedrich; Shahrokh F Shariat; Margit Fisch; Klaus Pantel; Sabine Riethdorf
Journal:  Eur Urol       Date:  2012-01-20       Impact factor: 20.096

2.  Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.

Authors:  Tetsutaro Hayashi; Roland Seiler; Htoo Zarni Oo; Wolfgang Jäger; Igor Moskalev; Shannon Awrey; Takashi Dejima; Tilman Todenhöfer; Na Li; Ladan Fazli; Akio Matsubara; Peter C Black
Journal:  J Urol       Date:  2015-06-03       Impact factor: 7.450

3.  Commentary on "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer." Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028-38.

Authors:  Ganesh S Palapattu
Journal:  Urol Oncol       Date:  2016-03-07       Impact factor: 3.498

4.  Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer.

Authors:  D Tvrdík; L Staněk; H Skálová; P Dundr; Z Velenská; C Povýšil
Journal:  Mol Med Rep       Date:  2012-05-17       Impact factor: 2.952

5.  Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Authors:  Stéphane Oudard; Stéphane Culine; Yann Vano; François Goldwasser; Christine Théodore; Thierry Nguyen; Eric Voog; Eugeniu Banu; Annick Vieillefond; Franck Priou; Gaël Deplanque; Gwenaëlle Gravis; Alain Ravaud; Jean Michel Vannetzel; Jean-Pascal Machiels; Xavier Muracciole; Marie-France Pichon; Jacques-Olivier Bay; Reza Elaidi; Corine Teghom; François Radvanyi; Philippe Beuzeboc
Journal:  Eur J Cancer       Date:  2014-11-15       Impact factor: 9.162

6.  The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer.

Authors:  Klaus Pantel; Catherine Alix-Panabières
Journal:  Cancer Discov       Date:  2012-10-23       Impact factor: 39.397

7.  Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer.

Authors:  Ajjai Alva; Terence Friedlander; Melanie Clark; Tamara Huebner; Stephanie Daignault; Maha Hussain; Cheryl Lee; Khaled Hafez; Brent Hollenbeck; Alon Weizer; Gayatri Premasekharan; Tony Tran; Christine Fu; Cristian Ionescu-Zanetti; Michael Schwartz; Andrea Fan; Pamela Paris
Journal:  J Urol       Date:  2015-04-23       Impact factor: 7.450

Review 8.  Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Authors:  Woonyoung Choi; Bogdan Czerniak; Andrea Ochoa; Xiaoping Su; Arlene Siefker-Radtke; Colin Dinney; David J McConkey
Journal:  Nat Rev Urol       Date:  2014-06-24       Impact factor: 14.432

9.  Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.

Authors:  Sabine Kasimir-Bauer; Oliver Hoffmann; Diethelm Wallwiener; Rainer Kimmig; Tanja Fehm
Journal:  Breast Cancer Res       Date:  2012-01-20       Impact factor: 6.466

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

View more
  4 in total

Review 1.  The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer.

Authors:  Sabine Riethdorf; Armin Soave; Michael Rink
Journal:  Transl Androl Urol       Date:  2017-12

2.  Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods.

Authors:  Emanuela Fina; Andrea Necchi; Stefano Bottelli; Carolina Reduzzi; Sara Pizzamiglio; Chiara Iacona; Maria Grazia Daidone; Paolo Verderio; Vera Cappelletti
Journal:  Dis Markers       Date:  2017-02-22       Impact factor: 3.434

3.  The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies.

Authors:  Zheng Zhang; Wei Fan; Qiaoling Deng; Shihui Tang; Ping Wang; Peipei Xu; June Wang; Mingxia Yu
Journal:  Oncotarget       Date:  2017-06-16

Review 4.  The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells.

Authors:  Alexandra C Kölbl; Udo Jeschke; Ulrich Andergassen
Journal:  Int J Mol Sci       Date:  2016-08-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.